HomeScreenerRNAProfile
D
48/100

Avidity Biosciences

RNARNA Therapeutics
📋
Analyst Summary
✓ VERIFIED2026-04-11

Avidity Biosciences (RNA) is the lead sponsor of 6 active clinical trials listed on ClinicalTrials.gov[4], including 3 Phase 3[1], 3 Phase 2[2], 1 Phase 1[3].

Trial NCT06411288[5] evaluates AOC 1001 (del-desiran) in DM1 with a target enrollment of 159 participants. Trial NCT07008469[6] evaluates Del-desiran (AOC 1001) in Myotonic Dystrophy Type 1 with a target enrollment of 230 participants. Trial NCT07038200[7] evaluates AOC-1020 in Facioscapulohumeral Muscular Dystrophy with a target enrollment of 200 participants.

No Form 4 insider filings for RNA were recorded at the SEC in the past 30 days[8].

Sources

  1. ClinicalTrials.gov (2026-04-11)
  2. ClinicalTrials.gov (2026-04-11)
  3. ClinicalTrials.gov (2026-04-11)
  4. ClinicalTrials.gov (2026-04-11)
  5. ClinicalTrials.gov · NCT06411288 (2026-01-22)
  6. ClinicalTrials.gov · NCT07008469 (2026-02-03)
  7. ClinicalTrials.gov · NCT07038200 (2026-01-20)
  8. SEC EDGAR · 0002093101 (2026-04-11)
🔬
Clinical Trials
6
NCT05747924FSHD, FSHD1, FSHD2, FMD, FMD2, Fascioscapulohumeral Muscular Dystrophy, Fascioscapulohumeral Muscular Dystrophy Type 1, Fascioscapulohumeral Muscular Dystrophy Type 2, Dystrophies, Facioscapulohumeral Muscular, Dystrophy, Facioscapulohumeral Muscular, Facioscapulohumeral Muscular Dystrophy 1, Facioscapulohumeral Muscular Dystrophy 2, Facio-Scapulo-Humeral Dystrophy, Atrophy, Facioscapulohumeral, Atrophies, Facioscapulohumeral, Facioscapulohumeral Atrophy, Muscular Dystrophies, Muscular Dystrophy, Facioscapulohumeral, FSH Muscular Dystrophy, Landouzy Dejerine Dystrophy, Landouzy-Dejerine Muscular Dystrophy, Dystrophies, Landouzy-Dejerine, Dystrophy, Landouzy-Dejerine, Landouzy-Dejerine Syndrome, Muscular Dystrophy, Landouzy Dejerine, Progressive Muscular Dystrophy, FSH
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT06244082DMD, Duchenne Muscular Dystrophy, Duchenne, Exon 44
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT06411288DM1, Myotonic Dystrophy, Myotonic Dystrophy 1, Myotonia, Myotonic Dystrophy Type 1 (DM1), Dystrophy Myotonic, Myotonic Disorders, Steinert Disease, Steinert, Myotonic Muscular Dystrophy
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT06547216FSHD, FSHD1, FSHD2, FMD, FMD2, Fascioscapulohumeral Muscular Dystrophy, Fascioscapulohumeral Muscular Dystrophy Type 1, Fascioscapulohumeral Muscular Dystrophy Type 2, Dystrophies, Facioscapulohumeral Muscular, Dystrophy, Facioscapulohumeral Muscular, Facioscapulohumeral Muscular Dystrophy 1, Facioscapulohumeral Muscular Dystrophy 2, Facio-Scapulo-Humeral Dystrophy, Atrophy, Facioscapulohumeral, Atrophies, Facioscapulohumeral, Facioscapulohumeral Atrophy, Muscular Dystrophies, Muscular Dystrophy, Facioscapulohumeral, FSH Muscular Dystrophy, Landouzy Dejerine Dystrophy, Landouzy-Dejerine Muscular Dystrophy, Dystrophies, Landouzy-Dejerine, Dystrophy, Landouzy-Dejerine, Landouzy-Dejerine Syndrome, Muscular Dystrophy, Landouzy Dejerine, Progressive Muscular Dystrophy, FSH
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT07008469Myotonic Dystrophy Type 1, DM1, Myotonic Dystrophy, Myotonia, Myotonic Dystrophy 1, Myotonic Disorders, Steinert Myotonic Dystrophy, Steinert Disease
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT07038200Facioscapulohumeral Muscular Dystrophy, FSHD, FSHD - Facioscapulohumeral Muscular Dystrophy, FSHD1, FSHD2, Fascioscapulohumeral Muscular Dystrophy, Fascioscapulohumeral Muscular Dystrophy Type 1, Fascioscapulohumeral Muscular Dystrophy Type 2, Facioscapulohumeral Muscular Dystrophy 1, Facioscapulohumeral Dystrophy, Facio-Scapulo-Humeral Dystrophy, Facioscapulohumeral Muscular Dystrophy 2, Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1), FSH Muscular Dystrophy, Landouzy Dejerine Dystrophy, Landouzy-Dejerine Muscular Dystrophy, Landouzy-Dejerine Syndrome
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
👤
Insider Activity
1
0 filings
Source ↗
sec_edgar · Retrieved 2026-04-11
Not financial advice. BiotechSigns profiles are AI-generated from verified public sources (ClinicalTrials.gov, SEC EDGAR) and are for informational purposes only. Always do your own due diligence before making investment decisions.
Score Breakdown
Score Trend
2026-04-132026-06-02
Signal Summary
PDUFA Dates0
Insider Filings1
Clinical Trials2
Data Provenance
cik1 verified
clinical trial6 verified
insider buy1 verified
trial count4 verified
Every claim backed by source URL from ClinicalTrials.gov or SEC EDGAR